Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.36 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.36 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20642409 | 0.89 | ALDH1A1 (0.39) | ALDH1A1CYP3A4HSD17B10RAB9ANPC1 | |
| SCHEMBL12672048 | 0.84 | RAB9A (0.37) | ALDH1A1CYP3A4HSD17B10RAB9ANPC1 | |
| SCHEMBL1671495 | 0.82 | KMT2A (0.39) | ALDH1A1CYP3A4HSD17B10RAB9ANPC1 | |
| SCHEMBL20763621 | 0.82 | RAB9A (0.36) | ALDH1A1CYP3A4HSD17B10RAB9ANPC1 | |
| SCHEMBL4227497 | 0.82 | RAB9A (0.36) | ALDH1A1CYP3A4HSD17B10RAB9ANPC1 | |
| SCHEMBL12198285 | 0.82 | KMT2A (0.39) | ALDH1A1CYP3A4HSD17B10RAB9ANPC1 | |
| SCHEMBL9608912 | 0.82 | KDM4E (0.47) | KDM4ELMNA | |
| SCHEMBL15730163 | 0.79 | PDE4B (0.41) | ALDH1A1CYP3A4HSD17B10RAB9ANPC1 | |
| SCHEMBL15730162 | 0.79 | ALOX5 (0.38) | ALDH1A1CYP3A4HSD17B10RAB9ANPC1 | |
| SCHEMBL18328100 | 0.79 | GPR84 (0.45) | ALDH1A1CYP3A4HSD17B10RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771738-B2 | Endoparasitic depsipeptides | ZOETIS SERVICES LLC (US) | 2023-10-03 | — | — | US | disclosed |
| US-10759808-B2 | Monofunctional intermediates for ligand-dependent target protein degradation | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190134012-A1 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION (GNF) | 2019-05-09 | — | — | US | disclosed |
| US-20190119289-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | UNIV MICHIGAN REGENTS (US) | 2019-04-25 | — | — | US | disclosed |
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
| WO-2017120194-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION (US) | 2017-07-13 | — | — | WO | disclosed |
| US-9695154-B2 | Heteroaryl inhibitors of sumo activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2017-05-18 | — | — | US | disclosed |
| US-9540343-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20160355504-A1 | HETEROARYL INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-12-08 | — | — | US | disclosed |
| WO-2016079711-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-05-26 | — | — | WO | disclosed |
| EP-2729448-B1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES INC (US) | 2015-09-09 | — | — | EP | disclosed |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20130012511-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME LLC | 2013-01-10 | — | — | US | disclosed |
| US-20120135975-A1 | Substituted Esters as Cannabinoid-1 Receptor Modulators | MERCK & CO., INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20110046152-A1 | Amide Compounds, Preparation Methods and Uses Thereof | SINOCHEM CORPORATION | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119289-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | MDM2, CD74, TNFSF10 | ALDH1A1 1474/4885CYP3A4 2050/4885HSD17B10 2950/4885 |
| US-20110046152-A1 | Amide Compounds, Preparation Methods and Uses Thereof | ACHE, MGAM, PGLS | ALDH1A1 1163/4885CYP3A4 1218/4885HSD17B10 4498/4885 |
| US-10759808-B2 | Monofunctional intermediates for ligand-dependent target protein degradation | MDM2, CD74, TNFSF10 | ALDH1A1 1474/4885CYP3A4 2050/4885HSD17B10 2950/4885 |
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | ALDH1A1 993/4885CYP3A4 1987/4885HSD17B10 1577/4885 |
| US-20130012511-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | PDE3B, PDE3A, GUCY1B1 | ALDH1A1 1570/4885CYP3A4 2236/4885HSD17B10 2052/4885 |
| US-11771738-B2 | Endoparasitic depsipeptides | VIP, PREP, VIPR1 | ALDH1A1 2109/4885CYP3A4 3009/4885HSD17B10 3772/4885 |
| US-20160355504-A1 | HETEROARYL INHIBITORS OF SUMO ACTIVATING ENZYME | SAE1, SUMO2, SUMO1 | ALDH1A1 1991/4885CYP3A4 733/4885HSD17B10 243/4885 |
| US-20120135975-A1 | Substituted Esters as Cannabinoid-1 Receptor Modulators | CNR1, CNR2, FAAH | ALDH1A1 2986/4885CYP3A4 853/4885HSD17B10 3891/4885 |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | ALDH1A1 649/4885CYP3A4 247/4885HSD17B10 368/4885 |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | ALDH1A1 649/4885CYP3A4 247/4885HSD17B10 368/4885 |
| US-20190134012-A1 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS | FGF1, COL2A1, FGFR3 | ALDH1A1 27/4885CYP3A4 4180/4885HSD17B10 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.